PODD Legal Deadline Notice: Important Insulet Deadline in Securities Fraud Class Action is Approaching – Investors Notified to Contact BFA Law by August 31

A securities fraud class action lawsuit has been filed on behalf of Insulet investors after its stock plummeted over 6% because of misrepresentation about the safety of Insulet’s Omnipod products.

A securities fraud class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Insulet, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/insulet-class-action-lawsuit .

Key Details of the Insulet ($PODD) Class Action:

Lead Plaintiff Deadline: August 31, 2026

Alleged Misconduct: Securities fraud relating to the safety of Insulet’s Omnipod products

Largest Alleged Stock Drop: March 12, 2026 – 6.88% Stock Drop

Court: U.S. District Court for the District of Massachusetts

Take Action: Contact BFA Law to discuss your rights

Insulet investors have until August 31, 2026 to ask the Court to be appointed to lead the case.

The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Insulet securities.

The class action is pending in the U.S. District Court for the District of Massachusetts. It is captioned Hu v. Insulet Corporation et al. , No. 26-cv-13062.

Why is Insulet Being Sued for Securities Fraud?

Insulet is primarily engaged in the development, manufacture, and sale of insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform.

The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Omnipod Eros”).

Throughout the relevant period, Insulet misrepresented the safety of its Omnipod products as well as its ability to efficiently produce “medical grade quality at consumer electronic scale.”

In reality, certain of Insulet’s products suffered from undisclosed manufacturing defects that put patient safety at risk.

Why did Insulet’s Stock Drop?

On March 12, 2026, Insulet disclosed that a manufacturing issue with its Omnipod® 5 Pods caused a “tear in the internal tubing that delivers insulin” resulting in insulin being released inside the Pod “instead of being fully infused into the body as intended.”

Accordingly, Insulet “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods.”

This news caused the price of Insulet stock to drop $16.23 per share, or 6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84 per share on March 13, 2026.

On May 26, 2026, Insulet announced another voluntary Medical Device Correction due to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and Omnipod Eros systems.

It again indicated that the manufacturing issue resulted in a tear in the tubing which “could result in insulin under-delivery.”

This news caused the price of Insulet stock to drop $7.79 per share, or 5.07%, from a closing price of $218.11 per share on May 26, 2026, to $146.01 per share on May 27, 2026.